Yvonne L. Eaglehouse
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Yvonne L. Eaglehouse has a total of 77 co-authors. Here are the top co-authors by number of shared publications:
- Kangmin Zhu
Murtha Cancer Center Research Program, Department of Surgery, Uniformed Services University of the Health Sciences, Bethesda, MD, USA; Department of Preventive Medicine and Biostatistics, Uniformed Services University of the Health Sciences, Bethesda, MD, USA; The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc., Bethesda, MD, USA
21 shared publications Sarah Darmon
Murtha Cancer Center Research Program, Department of Surgery, Uniformed Services University of the Health Sciences, Bethesda, MA; The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc., Bethesda, MA
17 shared publicationsCraig D. Shriver
Murtha Cancer Center Research Program, Department of Surgery, Uniformed Services University of the Health Sciences, Bethesda, MA
16 shared publications- Craig D. Shriver
Murtha Cancer Center Research Program, Department of Surgery, Uniformed Services University of the Health Sciences, Bethesda, USA
8 shared publications Kangmin Zhu
Murtha Cancer Center Research Program, Department of Surgery, Uniformed Services University of the Health Sciences, Bethesda, MA; The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc., Bethesda, MA
5 shared publications- Andrea M. Kriska
Department of Epidemiology, University of Pittsburgh, Pittsburgh, USA
4 shared publications
Latest Publications
- 19 October 2026
- Published by Wolters Kluwer Health in American Journal of Clinical Oncology
- Vol. 49 (12) , 600-606
Sex Differences in Postoperative Outcomes for Men and Women With Colon Cancer in the US Military Health System
Objectives: Biological, behavioral, and health care access differences between men and women may contribute to differences in colon cancer diagnosis and treatment. We compared postoperative outcomes between men and women with colon cancer in the universal access Military Health System (MHS) to better understand sex-based differences in surgery. Methods: We identified patients with stage I to III colon adenocarcinoma receiving surgery in the Military Cancer Epidemiology (MilCanEpi) database between 2001 and 2014. Thirty-day postoperative outcomes included general cardiovascular and respiratory complications; infections (surgical site [SSI], urinary tract [UTI], and systemic); gastrointestinal (GI) complications (hemorrhage, bowel obstruction, ileus, intra-abdominal abscess, and anastomotic leakage); and hospital readmissions. Modified Poisson regression estimated adjusted rate ratios (ARRs) and 95% CIs in association with biological sex for the outcomes. Results: The study included 1073 male (mean age=59.5±13.5 y) and 794 female (mean age=59.6±13.5 y) patients. In the 30-day postoperative period, general complication rates were not different by sex (ARR=1.03, 95% CI: 0.76-1.40 for women vs. men). Female sex was associated with higher rates of UTI (ARR=2.44, 95% CI: 1.63-3.65) and lower rates of GI complications (ARR=0.79, 95% CI: 0.69-0.90) relative to men. There were no sex differences in 30-day hospital readmissions (ARR=0.90, 95% CI: 0.76-1.08 for women vs. men). Conclusions: In the MHS, female sex was associated with higher rates of UTI and lower rates of GI complications relative to men undergoing colon cancer surgery. Factors other than health care access, such as biological differences in pelvic anatomy, physiology, or immune responses, may contribute to observed differences.
- 19 October 2026
- Published by Wolters Kluwer Health in American Journal of Clinical Oncology
- Vol. 49 (12) , 600-606
Sex Differences in Postoperative Outcomes for Men and Women With Colon Cancer in the US Military Health System
Objectives: Biological, behavioral, and health care access differences between men and women may contribute to differences in colon cancer diagnosis and treatment. We compared postoperative outcomes between men and women with colon cancer in the universal access Military Health System (MHS) to better understand sex-based differences in surgery. Methods: We identified patients with stage I to III colon adenocarcinoma receiving surgery in the Military Cancer Epidemiology (MilCanEpi) database between 2001 and 2014. Thirty-day postoperative outcomes included general cardiovascular and respiratory complications; infections (surgical site [SSI], urinary tract [UTI], and systemic); gastrointestinal (GI) complications (hemorrhage, bowel obstruction, ileus, intra-abdominal abscess, and anastomotic leakage); and hospital readmissions. Modified Poisson regression estimated adjusted rate ratios (ARRs) and 95% CIs in association with biological sex for the outcomes. Results: The study included 1073 male (mean age=59.5±13.5 y) and 794 female (mean age=59.6±13.5 y) patients. In the 30-day postoperative period, general complication rates were not different by sex (ARR=1.03, 95% CI: 0.76-1.40 for women vs. men). Female sex was associated with higher rates of UTI (ARR=2.44, 95% CI: 1.63-3.65) and lower rates of GI complications (ARR=0.79, 95% CI: 0.69-0.90) relative to men. There were no sex differences in 30-day hospital readmissions (ARR=0.90, 95% CI: 0.76-1.08 for women vs. men). Conclusions: In the MHS, female sex was associated with higher rates of UTI and lower rates of GI complications relative to men undergoing colon cancer surgery. Factors other than health care access, such as biological differences in pelvic anatomy, physiology, or immune responses, may contribute to observed differences.
- 28 July 2026
- Published by Elsevier in Clinical Genitourinary Cancer
- Vol. 24 (7) , 102632
Age at Diagnosis and Postoperative Outcomes Among Men Treated for Prostate Cancer in the U.S. Military Health System
- 28 July 2026
- Published by Elsevier in Clinical Genitourinary Cancer
- Vol. 24 (7) , 102632
Age at Diagnosis and Postoperative Outcomes Among Men Treated for Prostate Cancer in the U.S. Military Health System
- Open Access
- 1 April 2026
- Published by AME Publishing Company in Annals of Cancer Epidemiology
- Vol. 10, 15
Modifiable risk factors for pancreatic cancers: an editorial commentary
Modifiable risk factors for pancreatic cancers: an editorial commentary
- 1 April 2026
- Published by AME Publishing Company in Annals of Cancer Epidemiology
- Vol. 10, 15
Open AccessModifiable risk factors for pancreatic cancers: an editorial commentary
Modifiable risk factors for pancreatic cancers: an editorial commentary
- 12 February 2026
- Published by Oxford University Press (OUP) in Military Medicine
- Vol. 191 (9-10) , e2074-e2084
Age Comparisons of Endometrial Cancer Clinicopathology and Treatment in the United States Military Health System
Introduction: Endometrial cancer incidence is rising in the United States, including among women younger than 50 years, raising concern for women serving on active duty, retirees, and their dependents. Age-related differences in clinicopathologic features and treatment have been documented in the general U.S. population and the differences may be influenced by access to care. We aimed to study clinicopathologic and treatment features of women within the Department of War (DoW) Military Health System (MHS) to better understand age-related differences in tumor characteristics, surgical management, and adjuvant therapy by age in this universal access setting. Materials and Methods: We conducted a retrospective cohort study using the Military Cancer Epidemiology (MilCanEpi) database, which links the DoW cancer registry and medical claims data. Women diagnosed with endometrial cancer from 2001 to 2014 who underwent hysterectomy within 6 months of diagnosis were included. Modified Poisson regression was used to estimate adjusted risk ratios (ARRs) for advanced tumor stage (II-IV vs. I), aggressive histological subtypes (high-grade endometrioid endometrial carcinoma [EEC] or non-EEC vs. low-grade EEC), surgical approach, and adjuvant therapy (chemotherapy or radiation) by age group: 18-49, 50-64, and ≥65 years. Results: Among 1,223 patients, 16% were aged 18-49, 61% aged 50-64, and 23% aged ≥65. Compared with women aged 50-64, those aged 18-49 were less likely to have aggressive histologic subtypes (ARR = 0.65; 95% CI = 0.44-0.96), while those aged ≥65 were at higher risk for more aggressive histologic subtypes (ARR = 1.54; 95% CI = 1.25-1.90). No significant age-related differences were observed in tumor stage, time to surgery, surgical approach, or lymphadenectomy. Among patients with aggressive histologic subtypes (n = 287), receipt of adjuvant therapy did not differ significantly by age (18-49 years: ARR = 0.84, 95% CI = 0.58-1.21; ≥65 years: ARR = 0.92, 95% CI = 0.78-1.08) relative to women aged 50-64 years at diagnosis. Conclusions: Within the MHS, age-related differences in endometrial cancer were confined to tumor histology, with younger women less likely and older women more likely to present with aggressive subtypes. This is consistent with that reported in the general U.S. population. Importantly, no age-related differences were observed in surgical management or receipt of adjuvant therapy when adjusted for tumor features. This may suggest the role of healthcare access in mitigating age-related treatment gaps observed in the general population.
- 12 February 2026
- Published by Oxford University Press (OUP) in Military Medicine
- Vol. 191 (9-10) , e2074-e2084
Age Comparisons of Endometrial Cancer Clinicopathology and Treatment in the United States Military Health System
Introduction: Endometrial cancer incidence is rising in the United States, including among women younger than 50 years, raising concern for women serving on active duty, retirees, and their dependents. Age-related differences in clinicopathologic features and treatment have been documented in the general U.S. population and the differences may be influenced by access to care. We aimed to study clinicopathologic and treatment features of women within the Department of War (DoW) Military Health System (MHS) to better understand age-related differences in tumor characteristics, surgical management, and adjuvant therapy by age in this universal access setting. Materials and Methods: We conducted a retrospective cohort study using the Military Cancer Epidemiology (MilCanEpi) database, which links the DoW cancer registry and medical claims data. Women diagnosed with endometrial cancer from 2001 to 2014 who underwent hysterectomy within 6 months of diagnosis were included. Modified Poisson regression was used to estimate adjusted risk ratios (ARRs) for advanced tumor stage (II-IV vs. I), aggressive histological subtypes (high-grade endometrioid endometrial carcinoma [EEC] or non-EEC vs. low-grade EEC), surgical approach, and adjuvant therapy (chemotherapy or radiation) by age group: 18-49, 50-64, and ≥65 years. Results: Among 1,223 patients, 16% were aged 18-49, 61% aged 50-64, and 23% aged ≥65. Compared with women aged 50-64, those aged 18-49 were less likely to have aggressive histologic subtypes (ARR = 0.65; 95% CI = 0.44-0.96), while those aged ≥65 were at higher risk for more aggressive histologic subtypes (ARR = 1.54; 95% CI = 1.25-1.90). No significant age-related differences were observed in tumor stage, time to surgery, surgical approach, or lymphadenectomy. Among patients with aggressive histologic subtypes (n = 287), receipt of adjuvant therapy did not differ significantly by age (18-49 years: ARR = 0.84, 95% CI = 0.58-1.21; ≥65 years: ARR = 0.92, 95% CI = 0.78-1.08) relative to women aged 50-64 years at diagnosis. Conclusions: Within the MHS, age-related differences in endometrial cancer were confined to tumor histology, with younger women less likely and older women more likely to present with aggressive subtypes. This is consistent with that reported in the general U.S. population. Importantly, no age-related differences were observed in surgical management or receipt of adjuvant therapy when adjusted for tumor features. This may suggest the role of healthcare access in mitigating age-related treatment gaps observed in the general population.
- Open Access
- 6 February 2026
- Published by SAGE Publications in Cancer Control
- Vol. 33
Age at Breast Cancer Diagnosis and Short-Term Postoperative Outcomes for Women Treated in a Universal Health System
Introduction: Surgery is an essential component of breast cancer treatment. Surgical complications may impact receipt of adjuvant therapy and long-term outcomes. Differences in insurance coverage and access to care by patient age in the general U.S. population may affect breast cancer diagnosis and surgery and thus age comparisons in research. We compared postoperative outcomes following breast cancer surgery between age groups in the U.S. Military Health System, which provides beneficiaries access to comprehensive care across the lifespan. Methods: We identified women aged ≥18 years with stage I–III breast cancer diagnosed from 2001 to 2014 undergoing surgery without reconstruction in the MilCanEpi database. Multivariable Poisson regression estimated the adjusted risk ratios (ARRs) with 95% confidence intervals (CIs) in association with age at diagnosis (18-39, 40-49, 50-64, and ≥65) for 30-day general and breast complications (surgical site infection, seroma, hematoma, or lymphedema), reoperation, and hospital readmission while controlling for potential confounders. Results: The study included 7835 women who were 18-39 (9.2%), 40-49 (23.6%), 50-64 (42.7%), and ≥65 (24.5%). The overall risk of general or breast complications did not differ significantly by age when controlled for demographic, tumor, and treatment variables. However, women aged 40-49 had a statistically increased adjusted risk of seroma (ARR = 1.50; 95% CI = 1.03-2.18) compared to women aged 50-64. No significant age-related differences were observed for reoperation or hospital readmission after adjustment. Conclusion: In the Military Health System, the overall risk of 30-day postoperative complications and hospital readmissions were not statistically different by age after adjustment for clinical and demographic factors. The findings support that surgical decision-making continue to prioritize tumor characteristics, comorbidity burden, and other clinical factors rather than age alone when assessing perioperative risk.
- 6 February 2026
- Published by SAGE Publications in Cancer Control
- Vol. 33
Open AccessAge at Breast Cancer Diagnosis and Short-Term Postoperative Outcomes for Women Treated in a Universal Health System
Introduction: Surgery is an essential component of breast cancer treatment. Surgical complications may impact receipt of adjuvant therapy and long-term outcomes. Differences in insurance coverage and access to care by patient age in the general U.S. population may affect breast cancer diagnosis and surgery and thus age comparisons in research. We compared postoperative outcomes following breast cancer surgery between age groups in the U.S. Military Health System, which provides beneficiaries access to comprehensive care across the lifespan. Methods: We identified women aged ≥18 years with stage I–III breast cancer diagnosed from 2001 to 2014 undergoing surgery without reconstruction in the MilCanEpi database. Multivariable Poisson regression estimated the adjusted risk ratios (ARRs) with 95% confidence intervals (CIs) in association with age at diagnosis (18-39, 40-49, 50-64, and ≥65) for 30-day general and breast complications (surgical site infection, seroma, hematoma, or lymphedema), reoperation, and hospital readmission while controlling for potential confounders. Results: The study included 7835 women who were 18-39 (9.2%), 40-49 (23.6%), 50-64 (42.7%), and ≥65 (24.5%). The overall risk of general or breast complications did not differ significantly by age when controlled for demographic, tumor, and treatment variables. However, women aged 40-49 had a statistically increased adjusted risk of seroma (ARR = 1.50; 95% CI = 1.03-2.18) compared to women aged 50-64. No significant age-related differences were observed for reoperation or hospital readmission after adjustment. Conclusion: In the Military Health System, the overall risk of 30-day postoperative complications and hospital readmissions were not statistically different by age after adjustment for clinical and demographic factors. The findings support that surgical decision-making continue to prioritize tumor characteristics, comorbidity burden, and other clinical factors rather than age alone when assessing perioperative risk.
- Open Access
- 21 January 2026
- Published by SAGE Publications in Cancer Control
- Vol. 33
Comorbidity Level and Risk of 90-day and 18-month Complications Among Patients Undergoing Radical Prostatectomy for Prostate Cancer in the Military Health System
Introduction: Prostate cancer is frequently diagnosed at ages when men may also have comorbidity. Access to care may influence both comorbidity management and cancer treatment and recovery. We examined the association between comorbidity and postoperative outcomes among men with prostate cancer in the universal access Military Health System (MHS). Methods: We identified a cohort of men diagnosed with non-metastatic prostate adenocarcinoma from 2001-2014 who received radical prostatectomy (RP) within 1 year of diagnosis in the MilCanEpi database, which links the Department of War Cancer Registry and MHS Data Repository. We used ICD-9 diagnosis codes to capture 90-day postoperative general and genitourinary (GU) complications and hospital readmissions; and 18-month postoperative GU complications. Poisson regression estimated the adjusted risk ratios (ARRs) and 95% confidence intervals (CIs) for the outcomes associated with comorbidity (0, 1-2, or ≥3) measured using the Elixhauser Index. Results: The study included 5645 men with non-metastatic prostate cancer (mean age 57.9 ± 7.7 years) who received RP; 39.9% of patients had no comorbidity, 43.9% had 1-2 conditions, and 16.2% had ≥3 conditions. Patients with ≥3 comorbidities had statistically significant higher risks of 90-day general (ARR = 1.88, 95% CI = 1.34, 2.64) and GU (ARR = 1.20, 95% CI = 1.06, 1.36) complications and hospital readmission (ARR = 1.59, 95% CI = 1.12, 2.26) relative to men with no comorbidity. At 18-month post-RP, men with 1-2 comorbidities (ARR = 1.19, 95% CI = 1.05, 1.35) and ≥3 comorbidities (ARR = 1.32, 95% CI = 1.13, 1.55) had statistically significant higher risk of measured GU complications relative to men with no comorbidity. Conclusions: In the MHS, higher comorbidity was associated with an increased risk of 30-day and 18-month complications and 90-day readmissions following RP for prostate cancer. This study identifies a need for risk management strategies to reduce complication rates among men with higher comorbidity levels diagnosed with prostate cancer and treated by RP.
- 21 January 2026
- Published by SAGE Publications in Cancer Control
- Vol. 33
Open AccessComorbidity Level and Risk of 90-day and 18-month Complications Among Patients Undergoing Radical Prostatectomy for Prostate Cancer in the Military Health System
Introduction: Prostate cancer is frequently diagnosed at ages when men may also have comorbidity. Access to care may influence both comorbidity management and cancer treatment and recovery. We examined the association between comorbidity and postoperative outcomes among men with prostate cancer in the universal access Military Health System (MHS). Methods: We identified a cohort of men diagnosed with non-metastatic prostate adenocarcinoma from 2001-2014 who received radical prostatectomy (RP) within 1 year of diagnosis in the MilCanEpi database, which links the Department of War Cancer Registry and MHS Data Repository. We used ICD-9 diagnosis codes to capture 90-day postoperative general and genitourinary (GU) complications and hospital readmissions; and 18-month postoperative GU complications. Poisson regression estimated the adjusted risk ratios (ARRs) and 95% confidence intervals (CIs) for the outcomes associated with comorbidity (0, 1-2, or ≥3) measured using the Elixhauser Index. Results: The study included 5645 men with non-metastatic prostate cancer (mean age 57.9 ± 7.7 years) who received RP; 39.9% of patients had no comorbidity, 43.9% had 1-2 conditions, and 16.2% had ≥3 conditions. Patients with ≥3 comorbidities had statistically significant higher risks of 90-day general (ARR = 1.88, 95% CI = 1.34, 2.64) and GU (ARR = 1.20, 95% CI = 1.06, 1.36) complications and hospital readmission (ARR = 1.59, 95% CI = 1.12, 2.26) relative to men with no comorbidity. At 18-month post-RP, men with 1-2 comorbidities (ARR = 1.19, 95% CI = 1.05, 1.35) and ≥3 comorbidities (ARR = 1.32, 95% CI = 1.13, 1.55) had statistically significant higher risk of measured GU complications relative to men with no comorbidity. Conclusions: In the MHS, higher comorbidity was associated with an increased risk of 30-day and 18-month complications and 90-day readmissions following RP for prostate cancer. This study identifies a need for risk management strategies to reduce complication rates among men with higher comorbidity levels diagnosed with prostate cancer and treated by RP.
- Open Access
- 1 November 2025
- Published by AME Publishing Company in Gland Surgery
- Vol. 14 (11) , 2187-2199
Patient age at diagnosis and biological sex in association with postoperative outcomes of thyroidectomy for low-risk papillary thyroid cancer in the U.S. Military Health System
Background: In the United States (U.S.) population, thyroid cancer incidence, aggressiveness, and survival have been shown to vary by patient age at diagnosis and biological sex. Surgery is a primary treatment for low-risk thyroid cancer and surgical outcomes can greatly influence patient outcomes and survival. It is unknown whether patients differ in postoperative outcomes of thyroid cancer surgery by age at diagnosis and sex. We aimed to study the topic in the U.S. Military Health System (MHS) to address this gap in knowledge. Methods: We used the Military Cancer Epidemiology (MilCanEpi) database to study a cohort of patients aged 18 years and older diagnosed with T1-2N0M0 papillary thyroid cancer between 2001 and 2014 who received thyroidectomy surgery. We estimated the adjusted risk ratio (ARR) and 95% confidence intervals (CIs) in association with patient age at diagnosis and biological sex for 30-day general and local thyroid complications and hospital readmissions using multivariable Poisson regression. Results: The study included 2,041 patients with 2.3% experiencing a general complication, 12.1% a thyroid complication, and 13.9% a readmission within 30 days after surgery. Overall, rates of general and thyroid complications as a whole were not statistically different for patients aged 40–49 or 50 years and older relative to age 18–39 years in multivariable models. However, patients 50 years or older had a statistically lower risk of hypoparathyroidism (ARR =0.37; 95% CI: 0.19–0.73) and also lower rates of readmission (ARR =0.68; 95% CI: 0.49–0.93) compared to patients aged 18–39 years. There were no statistically significant differences in the outcomes for men compared to women. Conclusions: In the MHS, we observed some variation in risk of complications and readmissions by patient age at diagnosis for those undergoing thyroidectomy for T1-2N0M0 papillary thyroid cancer. More research is needed to understand the factors underlying lower risk of complications among older adults, or conversely, higher risk for complications among young adult patients with papillary thyroid cancer.
- 1 November 2025
- Published by AME Publishing Company in Gland Surgery
- Vol. 14 (11) , 2187-2199
Open AccessPatient age at diagnosis and biological sex in association with postoperative outcomes of thyroidectomy for low-risk papillary thyroid cancer in the U.S. Military Health System
Background: In the United States (U.S.) population, thyroid cancer incidence, aggressiveness, and survival have been shown to vary by patient age at diagnosis and biological sex. Surgery is a primary treatment for low-risk thyroid cancer and surgical outcomes can greatly influence patient outcomes and survival. It is unknown whether patients differ in postoperative outcomes of thyroid cancer surgery by age at diagnosis and sex. We aimed to study the topic in the U.S. Military Health System (MHS) to address this gap in knowledge. Methods: We used the Military Cancer Epidemiology (MilCanEpi) database to study a cohort of patients aged 18 years and older diagnosed with T1-2N0M0 papillary thyroid cancer between 2001 and 2014 who received thyroidectomy surgery. We estimated the adjusted risk ratio (ARR) and 95% confidence intervals (CIs) in association with patient age at diagnosis and biological sex for 30-day general and local thyroid complications and hospital readmissions using multivariable Poisson regression. Results: The study included 2,041 patients with 2.3% experiencing a general complication, 12.1% a thyroid complication, and 13.9% a readmission within 30 days after surgery. Overall, rates of general and thyroid complications as a whole were not statistically different for patients aged 40–49 or 50 years and older relative to age 18–39 years in multivariable models. However, patients 50 years or older had a statistically lower risk of hypoparathyroidism (ARR =0.37; 95% CI: 0.19–0.73) and also lower rates of readmission (ARR =0.68; 95% CI: 0.49–0.93) compared to patients aged 18–39 years. There were no statistically significant differences in the outcomes for men compared to women. Conclusions: In the MHS, we observed some variation in risk of complications and readmissions by patient age at diagnosis for those undergoing thyroidectomy for T1-2N0M0 papillary thyroid cancer. More research is needed to understand the factors underlying lower risk of complications among older adults, or conversely, higher risk for complications among young adult patients with papillary thyroid cancer.
- 15 October 2025
- Published by Oxford University Press (OUP) in JNCI Cancer Spectrum
- Vol. 9 (6)
Short-term surgical outcomes in patients with early- versus average-onset colon adenocarcinoma in the Military Health System
Background: Diagnosis, treatment, and outcomes of colon cancer in the United States differ between patients younger than age 50 (early-onset colon cancer [EOCC]) and those age 50 or older (average-onset [AOCC]) and may be impacted by access to care. Less is known about surgical quality and postoperative outcomes between patients with EOCC and AOCC. This study aimed to compare patients with EOCC and AOCC in surgical aspects and 30-day postoperative complications and readmissions in the Military Health System. Methods: The cohort included patients diagnosed with stage I-III colon adenocarcinoma between 2001 and 2014 who received surgery. Poisson regression with robust standard errors estimated the adjusted risk ratios (ARRs) and 95% confidence intervals (CIs) in association with age at diagnosis for the outcomes. Results: Among 333 patients with EOCC and 1369 patients with AOCC, there were no statistically significant differences in surgical delay, positive margins, or inadequate lymphadenectomy. Patients with EOCC had statistically higher adjusted 30-day risk of any complication (ARR = 1.31, 95% CI = 1.05 to 1.63), inclusive of general surgical (ARR = 1.64, 95% CI = 1.14 to 2.38) and gastrointestinal (ARR = 1.29, 95% CI = 1.00 to 1.65) complications, relative to patients with AOCC. There was no statistically significant difference in 30-day readmission for patients with EOCC (ARR = 1.30, 95% CI = 0.84 to 202) compared with patients with AOCC. Conclusion: In the Military Health System, patients with EOCC had higher adjusted 30-day risk of complications following surgery compared with patients with AOCC. This finding may have implications for care delivery and postoperative management of patients with EOCC to reduce complication burden and achieve optimal outcomes.
- 15 October 2025
- Published by Oxford University Press (OUP) in JNCI Cancer Spectrum
- Vol. 9 (6)
Short-term surgical outcomes in patients with early- versus average-onset colon adenocarcinoma in the Military Health System
Background: Diagnosis, treatment, and outcomes of colon cancer in the United States differ between patients younger than age 50 (early-onset colon cancer [EOCC]) and those age 50 or older (average-onset [AOCC]) and may be impacted by access to care. Less is known about surgical quality and postoperative outcomes between patients with EOCC and AOCC. This study aimed to compare patients with EOCC and AOCC in surgical aspects and 30-day postoperative complications and readmissions in the Military Health System. Methods: The cohort included patients diagnosed with stage I-III colon adenocarcinoma between 2001 and 2014 who received surgery. Poisson regression with robust standard errors estimated the adjusted risk ratios (ARRs) and 95% confidence intervals (CIs) in association with age at diagnosis for the outcomes. Results: Among 333 patients with EOCC and 1369 patients with AOCC, there were no statistically significant differences in surgical delay, positive margins, or inadequate lymphadenectomy. Patients with EOCC had statistically higher adjusted 30-day risk of any complication (ARR = 1.31, 95% CI = 1.05 to 1.63), inclusive of general surgical (ARR = 1.64, 95% CI = 1.14 to 2.38) and gastrointestinal (ARR = 1.29, 95% CI = 1.00 to 1.65) complications, relative to patients with AOCC. There was no statistically significant difference in 30-day readmission for patients with EOCC (ARR = 1.30, 95% CI = 0.84 to 202) compared with patients with AOCC. Conclusion: In the Military Health System, patients with EOCC had higher adjusted 30-day risk of complications following surgery compared with patients with AOCC. This finding may have implications for care delivery and postoperative management of patients with EOCC to reduce complication burden and achieve optimal outcomes.
- Open Access
- 6 October 2025
- Published by Wiley in Cancer Medicine
- Vol. 14 (19) , e71292
Impact of COVID ‐19 on Time to Treat Breast Cancer and Racial Disparities Among Women in the Military Health System From FY2018 ‐2022
Background: Breast cancer is the most diagnosed cancer among women in the United States, and early identification and initiation of treatment are critical to improving outcomes. This study aims to investigate the breast cancer time to treat trends among women in the Military Health System before and during the COVID‐19 pandemic and if racial or socioeconomic disparities existed in timely treatment. Methods: A retrospective cohort study of all female MHS beneficiaries ages 18–63 years during fiscal years 2018–2022. Incident breast cancer was defined as one inpatient or three outpatient diagnoses of breast cancer within a 90‐day period and no previous breast cancer diagnosis in the 3 years prior. Time to treatment was calculated in days and timely treatment was identified if received within 90 days (surgical intervention) or 120 days (chemotherapy and radiation) after initial diagnosis. Study analyses included a t ‐test and Kaplan–Meier curve for time to treatment and an adjusted modified Poisson regression for the relative risk of timely treatment. Results: A cohort of 14,286 women with incident breast cancer was identified; 94% received timely treatment. The average time to treatment was greater during the pandemic period (47.7 days, 95% CI = 46.6–48.7) compared to the pre‐pandemic period (44.8 days, 95% CI = 43.7–45.9). Regression results indicated no difference in the likelihood of timely treatment in the pandemic period (0.99 aRR, 0.98–1.01 95% CI), no racial or socioeconomic disparities, and timely treatment was more likely to be received in the direct care setting (aRR = 1.04, 95% CI = 1.01–1.07). Conclusion: Despite facing access to care challenges compounded by the COVID‐19 pandemic, the MHS was able to provide timely treatment to women for incident breast cancer. In addition, this study observed no racial or socioeconomic disparities in the timely treatment of breast cancer in a population with equal access to care.
- 6 October 2025
- Published by Wiley in Cancer Medicine
- Vol. 14 (19) , e71292
Open AccessImpact of COVID ‐19 on Time to Treat Breast Cancer and Racial Disparities Among Women in the Military Health System From FY2018 ‐2022
Background: Breast cancer is the most diagnosed cancer among women in the United States, and early identification and initiation of treatment are critical to improving outcomes. This study aims to investigate the breast cancer time to treat trends among women in the Military Health System before and during the COVID‐19 pandemic and if racial or socioeconomic disparities existed in timely treatment. Methods: A retrospective cohort study of all female MHS beneficiaries ages 18–63 years during fiscal years 2018–2022. Incident breast cancer was defined as one inpatient or three outpatient diagnoses of breast cancer within a 90‐day period and no previous breast cancer diagnosis in the 3 years prior. Time to treatment was calculated in days and timely treatment was identified if received within 90 days (surgical intervention) or 120 days (chemotherapy and radiation) after initial diagnosis. Study analyses included a t ‐test and Kaplan–Meier curve for time to treatment and an adjusted modified Poisson regression for the relative risk of timely treatment. Results: A cohort of 14,286 women with incident breast cancer was identified; 94% received timely treatment. The average time to treatment was greater during the pandemic period (47.7 days, 95% CI = 46.6–48.7) compared to the pre‐pandemic period (44.8 days, 95% CI = 43.7–45.9). Regression results indicated no difference in the likelihood of timely treatment in the pandemic period (0.99 aRR, 0.98–1.01 95% CI), no racial or socioeconomic disparities, and timely treatment was more likely to be received in the direct care setting (aRR = 1.04, 95% CI = 1.01–1.07). Conclusion: Despite facing access to care challenges compounded by the COVID‐19 pandemic, the MHS was able to provide timely treatment to women for incident breast cancer. In addition, this study observed no racial or socioeconomic disparities in the timely treatment of breast cancer in a population with equal access to care.
- 16 September 2025
- Published by Elsevier in Surgical Oncology
- Vol. 63, 102295
Short-term surgical outcomes for colon adenocarcinoma: Racial-Ethnic comparisons in a universal access health system
- 16 September 2025
- Published by Elsevier in Surgical Oncology
- Vol. 63, 102295
Short-term surgical outcomes for colon adenocarcinoma: Racial-Ethnic comparisons in a universal access health system